Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 16, 2011 Brian Orelli	Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech.
The Motley Fool August 29, 2011 Brian Orelli	We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply.
The Motley Fool September 1, 2010 Brian Orelli	Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge.
The Motley Fool August 10, 2011 Jim Mueller	Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here.
The Motley Fool February 1, 2008 Brian Lawler	Alexion Looks for a Bigger Niche Alexion Pharmaceutical announces sales of its rare blood disorder medication should expand in 2008.
The Motley Fool January 5, 2012 David Williamson	Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%.
The Motley Fool April 30, 2004 Charly Travers	Sales Weakness From InterMune Biotechnology company InterMune would seem to be in good shape with a drug, Actimmune (which helps boost the immune system of cancer patients and others). The drug, however, has been showing quarterly sales weakness since early 2003, a trend that now seems like it may continue into the future.
The Motley Fool November 23, 2011 Brian Orelli	I Was Wrong About Dendreon But maybe not in the long term.
The Motley Fool April 30, 2010 Brian Orelli	Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it?
The Motley Fool June 1, 2010 Brian Orelli	Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile.
The Motley Fool May 10, 2006 Brian Lawler	Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note.
The Motley Fool November 25, 2011 Brian Orelli	7 Black Friday Biotech Bargains Get in at the right time to maximize your returns.
The Motley Fool November 3, 2011 David Williamson	Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100.
The Motley Fool March 10, 2010 Brian Orelli	Up 160% With Room to Run You've got to love biotech and InterMune.
The Motley Fool February 3, 2009 Brian Orelli	InterMune Batting .500 The results weren't exactly what Rule Breakers pick InterMune was looking for, but things could have been worse -- and the stock is up 38% today on the news.
The Motley Fool March 11, 2011 Brian Orelli	Sales Can Quadruple, More to Come Dendreon is still supply-constrained, but less than before.
The Motley Fool August 8, 2011 Luke Timmerman	Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Is Dendreon doomed?
The Motley Fool December 17, 2010 Brian Orelli	An Overnight Double: Santa Visits InterMune in Europe The Committee for Medicinal Products for Human Use issued a positive recommendation for the approval of InterMune's idiopathic pulmonary fibrosis treatment, Esbriet, sending shares up 140%.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool July 1, 2011 Brian Orelli	Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool November 18, 2010 Brian Orelli	Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge.
The Motley Fool October 26, 2011 Brian Orelli	Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest.
The Motley Fool August 4, 2011 Brian Orelli	Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse?
The Motley Fool December 30, 2011 Brian Orelli	A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool August 4, 2010 Brian Orelli	Dendreon Doubles Up The biotech enjoys twice as much revenue month over month.
The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool May 3, 2011 Brian Orelli	Brakes Are Off at Dendreon Ramping up sales, one month at a time.
The Motley Fool March 4, 2010 Brian Orelli	Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing.
The Motley Fool January 15, 2012 Brian Orelli	3 Lessons From the J.P. Morgan Health-Care Confab After 30 years, the conference still offers useful takeaways. This years: Some biotechs never die... In the United States, more people die from flu each year than die from HIV AIDS... Drug launches are back (maybe)...
The Motley Fool April 28, 2011 Brian Orelli	Celgene Gets No Love The market shrugs off a solid quarter.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool January 7, 2011 Brian Orelli	Dendreon Heads Across the Pond A pathway to Provenge approval in the EU.
The Motley Fool January 10, 2011 Brian Orelli	By the Way, We Need to Run Another Trial InterMune has decided to run a new trial to gain U.S. approval on its idiopathic pulmonary fibrosis drug.
The Motley Fool November 2, 2011 David Williamson	After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock.
The Motley Fool April 30, 2007 Brian Lawler	Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
The Motley Fool January 28, 2011 Brian Orelli	Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase.
The Motley Fool September 22, 2010 Brian Orelli	A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead.
The Motley Fool June 19, 2009 Brian Orelli	Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk.
The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
The Motley Fool January 13, 2009 Brian Orelli	Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can.
The Motley Fool May 10, 2005 Charly Travers	Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in?
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool March 6, 2007 Brian Lawler	InterMune Swoons Shares of InterMune fall after it announces negative clinical trial results for one of its drugs.
The Motley Fool September 28, 2010 Brian Orelli	It's Up! It's Down! It's Dendreon! The joys of biotech.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool November 16, 2010 Luke Timmerman	Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug.